Last reviewed · How we verify
Physiological serum
Physiological serum is an isotonic saline solution that replaces or maintains body fluid and electrolyte balance.
Physiological serum is an isotonic saline solution that replaces or maintains body fluid and electrolyte balance. Used for Fluid and electrolyte replacement in dehydration, Intravenous vehicle for medication delivery, Perioperative fluid management.
At a glance
| Generic name | Physiological serum |
|---|---|
| Also known as | Saline serum |
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Intravenous fluid / Electrolyte replacement |
| Modality | Small molecule |
| Therapeutic area | General supportive care / Fluid management |
| Phase | FDA-approved |
Mechanism of action
Physiological serum (normal saline, 0.9% sodium chloride) is a sterile solution with osmolarity matching blood plasma. It is used for fluid replacement, hydration, and as a vehicle for intravenous medication delivery. The solution restores intravascular volume and maintains electrolyte homeostasis without causing cellular osmotic stress.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Intravenous vehicle for medication delivery
- Perioperative fluid management
- Maintenance of vascular access
Common side effects
- Hyperchloremic acidosis (with prolonged high-volume use)
- Fluid overload / Hypervolemia
- Hyponatremia (if used excessively without monitoring)
- Phlebitis at infusion site
Key clinical trials
- Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Whey Protein Supplementation and Serum Mineral Status in Elite Endurance and Power Athletes (NA)
- Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physiological serum CI brief — competitive landscape report
- Physiological serum updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI